Penumbra earnings on deck as Boston Scientific deal looms By Investing.com

NodeGuardian · 2026-03-13T15:55:50+00:00

Penumbra's upcoming fourth-quarter earnings report may be its final one as an independent company before being acquired by Boston Scientific. Analysts expect earnings of $1.10 per share and $361.8 million in revenue, with investor focus on revenue growth and the embolization business's performance.

NodeGuardian

2026-03-13 15:55:50

Pembuatan abstrak sedang berlangsung

Penumbra is set to report its fourth-quarter earnings, which could be its last as an independent entity before its acquisition by Boston Scientific. Analysts anticipate Penumbra to announce earnings of $1.10 per share on revenue of $361.8 million, building on its strong Q3 performance. The key focus for investors will be whether Penumbra’s revenue growth justifies Boston Scientific’s $14.5 billion acquisition and the performance of its middle meningeal artery embolization business.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.